MapLight Therapeutics (MPLT) Net Income towards Common Stockholders (2024 - 2025)

MapLight Therapeutics' (MPLT) quarterly Net Income towards Common Stockholders came in at -$80.9 million in Q4 2025, down 269.81% year-on-year from $47.6 million in Q4 2024, and down 170.15% quarter-over-quarter from -$29.9 million in Q3 2025.

MapLight Therapeutics (MPLT) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends

MapLight Therapeutics has disclosed Net Income towards Common Stockholders across 2 years of filings, most recently posting -$80.9 million for Q4 2025.

  • Net Income towards Common Stockholders for Q4 2025 came in at -$80.9 million, down 269.81% year-over-year; the trailing twelve-month figure through Dec 2025 was -$152.5 million (changed N/A YoY), and the FY2025 annual result was -$163.6 million, down 108.52% from the prior year.
  • Net Income towards Common Stockholders came in at -$80.9 million for Q4 2025 at MapLight Therapeutics, down from -$29.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$19.8 million in Q3 2024 to a low of -$80.9 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 MapLight Therapeutics 248.88 Mn 248.88 Mn - -80.91 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -80.91 Mn
Sep 30, 2025 -29.95 Mn
Dec 31, 2024 -21.88 Mn
Sep 30, 2024 -19.81 Mn